Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in PubMed. This abstract is what is used to create the fingerprint of the publication. If any grants are referenced by the publication, they will be listed here as well.
Nanoparticle and iron chelators as a potential novel Alzheimer therapy.
Gang Liu; Ping Men; George Perry; Mark A Smith (Profiled Authors: Smith, Mark A; Perry, George)
Department of Radiology, University of Utah, Salt Lake City, Utah, USA.
Methods in molecular biology (Clifton, N.J.) 2010;610():123-44.
Current therapies for Alzheimer disease (AD) such as the acetylcholinesterase inhibitors and the latest NMDA receptor inhibitor, Namenda, provide moderate symptomatic delay at various stages of the disease, but do not arrest the disease progression or bring in meaningful remission. New approaches to the disease management are urgently needed. Although the etiology of AD is largely unknown, oxidative damage mediated by metals is likely a significant contributor since metals such as iron, aluminum, zinc, and copper are dysregulated and/or increased in AD brain tissue and create a pro-oxidative environment. This role of metal ion-induced free radical formation in AD makes chelation therapy an attractive means of dampening the oxidative stress burden in neurons. The chelator desferrioxamine, FDA approved for iron overload, has shown some benefit in AD, but like many chelators, it has a host of adverse effects and substantial obstacles for tissue-specific targeting. Other chelators are under development and have shown various strengths and weaknesses. Here, we propose a novel system of chelation therapy through the use of nanoparticles. Nanoparticles conjugated to chelators show unique ability to cross the blood-brain barrier (BBB), chelate metals, and exit through the BBB with their corresponding complexed metal ions. This method may provide a safer and more effective means of reducing the metal load in neural tissue, thus attenuating the harmful effects of oxidative damage and its sequelae. Experimental procedures are presented in this chapter.
1 Originating Grant
-
1.
SMITH, MARK A
Role of Cell Cycle in Neurodegeneration
1 March 2008 - 28 February 2013
NATIONAL INSTITUTE ON AGING
Total Funding: $ 960,623
Scientific Context
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts and related grants with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Related Grants
-
1.
Zhu, Xiongwei
Metal Ion is Critical in amyloid beta Induced JNK Activation
1 July 2006 - 30 June 2010
NATIONAL INSTITUTE ON AGING
Total Funding: $ 981,634
-
2.
Rogers, Jack T
RNA Therapeutics and Abeta Precursor Protein Translation
1 August 2003 - 31 July 2007
NATIONAL INSTITUTE ON AGING
Total Funding: $ 1,192,021
Related Publications
-
1.
2012Gang Liu; Ping Men; Xiongwei Zhu; George Perry
Therapeutic delivery 2012;3(5):571-4. -
2.
2012David J Bonda; Gang Liu; Ping Men; George Perry; Mark A Smith; Xiongwei Zhu
CNS & neurological disorders drug targets 2012;11(1):81-5. -
3.
2006Gang Liu; Ping Men; Peggy L R Harris; Raj K Rolston; George Perry; Mark A Smith
Neuroscience letters 2006;406(3):189-93.
Related Topics
Appears in this Publication
Related Experts
Author of this Publication
-
Internal ExpertsPublications
-
610









-
540









-
65









-
252









-
205









-
691










